Regulation

Feb. 18 Quick Takes: Label expansion for Entresto; plus Amgen, Sesen, BeiGene, Cortexyme and more

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA approved Entresto sacubitril/valsartan to reduce the risk of cardiovascular death and hospitalization